pSILAC quantitative immunopeptidomics with Peptide-PRISM
downstream-application
pSILAC quantitative immunopeptidomics with Peptide-PRISM: downstream-application. Pulsed SILAC labelling combined with Peptide-PRISM de novo-based identification and MaxQuant quantification tracks how MAPK inhibition reshapes the melanoma…
Pulsed SILAC labelling combined with Peptide-PRISM de novo-based identification and MaxQuant quantification tracks how MAPK inhibition reshapes the melanoma immunopeptidome, revealing cryptic HLA peptides.
| Kind | downstream-application |
| Deep learning | no |
| Acquisition | DDA |
| Application area | Immunopeptidomics / neoantigen |
Paper describing it
- SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells (2025, Frontiers in Immunology, peer-reviewed)